Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Labo Euromedis's OCF Yield % or its related term are showing as below:
During the past 13 years, the highest OCF Yield % of Labo Euromedis was 137.57%. The lowest was -7.46%. And the median was 6.34%.
STU:61R's OCF Yield % is not ranked *
in the Medical Distribution industry.
Industry Median: 5.645 * Ranked among companies with meaningful OCF Yield % only.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Labo Euromedis OCF Yield % Related Terms
Labo Euromedis OCF Yield % Historical Data
* Premium members only.
The historical data trend for Labo Euromedis's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Labo Euromedis's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labo Euromedis OCF Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Labo Euromedis's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Labo Euromedis's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labo Euromedis (STU:61R) has a OCF Yield % of 0.00 as of Jul. 13, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Labo Euromedis and its competitors. According to the industry distribution chart, Labo Euromedis ranks #999999 out of 116 companies in the Medical Distribution industry.
Is Labo Euromedis' OCF Yield % too high?
Labo Euromedis' current OCF Yield % is 0.00. Based on the distribution chart, Labo Euromedis ranks #999999 out of 116 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Labo Euromedis has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labo Euromedis' OCF Yield % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Labo Euromedis ranks #999999 out of 116 companies for OCF Yield %. This places Labo Euromedis in the lower half of its industry. The industry median OCF Yield % is 5.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Distribution company?
The median OCF Yield % among Medical Distribution companies is 5.65, based on 116 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Labo Euromedis and its competitors. For the Medical Distribution industry, the median OCF Yield % is 5.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labo Euromedis's current OCF Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labo Euromedis stock overvalued right now?
Based on GuruFocus' analysis, Labo Euromedis (STU:61R) is currently considered Modestly Overvalued. The stock's GF Value™ is €4.39, compared to a current price of €4.88 — trading 11.2% above its estimated fair value. The current OCF Yield % is 0.00. Labo Euromedis' overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Labo Euromedis (STU:61R), the current OCF Yield % is 0.00 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labo Euromedis (STU:61R) Overvalued in 2026?
Based on GuruFocus' analysis, Labo Euromedis stock appears to be overvalued.
The current stock price of €4.88 is trading 11.2% above its estimated GF Value™ of €4.39.
GuruFocus considers Labo Euromedis to be Modestly Overvalued.
Key valuation signals for STU:61R:
OCF Yield %: 0.00
GF Value™: €4.39 vs. price of €4.88 (11.2% above fair value)
No single metric tells the full story. See the STU:61R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labo Euromedis is engaged in medical devices. It is engaged in the design, manufacture, rental and export of medical and surgical equipment and products.
68GF Score
Get the complete analysis for STU:61R
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:61R has been successfully added to your 
